Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects.

Autor: Kanter J; Hematology-Oncology, The University of Alabama at Birmingham, Birmingham, AL., Smith WR; Division of General Internal Medicine, Virginia Commonwealth University, Richmond, VA., Desai PC; Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH., Treadwell M; University of California San Francisco Benioff Children's Hospitals, Oakland, CA., Andemariam B; New England Sickle Cell Institute, Neag Comprehensive Cancer Center, University of Connecticut Health, Farmington, CT., Little J; Comprehensive Sickle Cell Disease Program, The University of North Carolina at Chapel Hill, Chapel Hill, NC., Nugent D; Center for Inherited Blood Disorders, Orange, CA.; Children's Hospital of Orange County (CHOC), Orange, CA., Claster S; Center for Inherited Blood Disorders, Orange, CA.; Martin Luther King, Jr. (MLK) Outpatient Center, Los Angeles, CA., Manwani DG; Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY., Baker J; Center for Inherited Blood Disorders, Orange, CA., Strouse JJ; Division of Hematology and.; Division of Pediatric Hematology-Oncology, Duke University, Durham, NC., Osunkwo I; Sickle Cell Disease Enterprise, The Levine Cancer Institute, Atrium Health, Charlotte, NC., Stewart RW; General Internal Medicine, Johns Hopkins University, Baltimore, MD., King A; Pediatric Hematology and Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO., Shook LM; Division of Hematology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH., Roberts JD; Department of Internal Medicine, Yale New Haven Health, New Haven, CT; and., Lanzkron S; Department of Medicine, School of Medicine, The Johns Hopkins University, Baltimore, MD.

Publikováno v: Blood advances [Blood Adv] 2020 Aug 25; Vol. 4 (16), pp. 3804-3813.

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up

Autor: Bridges, K., Telfer, M., Ataga, Kenneth, Orringer, E., Hoehner, C., Hernandez, S., Valdez, S., Temple, D., Shurin, S., Johnson-Telfair, A., Hagar, W., Vichinsky, E., Smith, Wally, Steinberg, Martin H., Kleman, K., Rosse, W., Waller, L., Barber, Y., Chow, J., Gascon, P., Winograd, C., Di Paolo, P., Hui, M., Moshang, J., Olivieri, N., Dorn, L., Siteman, J., Embury, S., Eckman, J., Ballas, Samir K., Anderson, A., White, L., Harrington, T., Talischy-Zahed, N., Shaw, D., Scott, B., Waclawiw, Myron A., Labrousse, W., Adler, B., Phillips, G., Bigelow, C., Armstrong, F. Danny, Chiarucci, K., Childerie, S., McLaughlin, K., Mandell, E., DeCastro, Laura, Claster, S., Knors, V., Gargiulo, S., Jones, S., Tynan, B., Saunthararajah, Y., Saunders, T., Maddox, B., Hackney-Stevens, E., Keverline, L., Gardner, D., Carter-Randall, E., Schmidt, B., Tracy, A., Davies, D., Carlos, T., Kutlar, Abdullah, Finke, H., Nwokolo, C., Perlin, E., Onyekwere, O. C., Okam, M., Peace, D., Milner, P., Koshy, M., Sheikhai, M., Daitch, L., Swerdlow, Paul, Pendarvis, G., Harrell, R., Case, E., Brenner, A., Bailey, J. H., Strayhorn, D., Prchal, J., Ramirez, G., Dosik, H., Platt, A., McGee, M., Lewis, N., Castro, Oswaldo, Palmer, A., Wilkes, E., Braddock, J., Sabahi, V., Pegelow, C., Bellevue, R., McArdle, T., O'Brien, R., Williams, K., Usry, L., Eskridge, L., Berman, B., Allen, G. E., Earles, A., Bryan, M., Davis, A., Rodriguez, E. M., Souffrant, H., Genther, K., McCarthy, William F., Roundtree-Schmotzer, A., Ryans, P.

A randomized, controlled clinical trial established the efficacy and safety of short-term use of hydroxyurea in adult sickle cell anemia. To examine the risks and benefits of long-term hydroxyurea usage, patients in this trial were followed for 17.5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::43f4a9c09122d8022b7db612076af118

Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis.

Autor: Khargekar, Naveen¹ (AUTHOR) naveenkhargekar@gmail.com, Banerjee, Anindita² (AUTHOR), Athalye, Shreyasi² (AUTHOR), Mahajan, Namrata¹ (AUTHOR), Kargutkar, Neha¹ (AUTHOR), Tapase, Prashant³ (AUTHOR), Madkaikar, Manisha³ (AUTHOR)

Publikováno v: Systematic Reviews. 2/8/2024, Vol. 13 Issue 1, p1-11. 11p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.